115 related articles for article (PubMed ID: 3802111)
1. Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.
Roberts JD; Stewart JA; McCormack JJ; Krakoff IR; Culham CA; Hartshorn JN; Newman RA; Haugh LD; Young JA
Cancer Treat Rep; 1987 Feb; 71(2):141-9. PubMed ID: 3802111
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.
Trump DL; Tutsch KD; Koeller JM; Tormey DC
Cancer Res; 1985 Jun; 45(6):2853-8. PubMed ID: 3986812
[TBL] [Abstract][Full Text] [Related]
4. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193).
Balis FM; Lange BJ; Packer RJ; Holcenberg JS; Ettinger LJ; Sallan SE; Heideman RL; Zimm S; Smithson WA; Cogliano-Shutta NA
Cancer Res; 1985 Oct; 45(10):5169-72. PubMed ID: 4027992
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
8. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
12. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
14. Tiazofurin: molecular and clinical action.
Weber G; Prajda N; Abonyi M; Look KY; Tricot G
Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
[TBL] [Abstract][Full Text] [Related]
15. Critical issues in chemotherapy with tiazofurin.
Weber G
Adv Enzyme Regul; 1989; 29():75-95. PubMed ID: 2699155
[TBL] [Abstract][Full Text] [Related]
16. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
[TBL] [Abstract][Full Text] [Related]
17. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
18. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.
Rowinsky EK; Noe DA; Ettinger DS; Christian MC; Lubejko BG; Fishman EK; Sartorius SE; Boyd MR; Donehower RC
Cancer Res; 1993 Apr; 53(8):1794-801. PubMed ID: 8467498
[TBL] [Abstract][Full Text] [Related]
20. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
